- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04303234
Assess Intraoperative Pain for Restorative Treatment of Maxillary 1st Permanent Molars Using Artinibsa Versus Artpharma in Children During Infiltration Technique
March 10, 2020 updated by: Amani Hamed Hashem AL-Aidaros, Cairo University
Intraoperative Pain During Restorative Treatment Of Maxillary First Permanent Molars Using Artinibsa Versus Artpharma In Children After Infiltration Technique: A Randomized Clinical Trial
The aim of this study is to assess Intraoperative pain for restorative treatment of Maxillary First Permanent Molars using Artinibsa Versus Artpharma in children during infiltration technique.
Study Overview
Detailed Description
Local anesthesia is very important during dental procedure because it's a temporary loss of sensation which will lead to decrease the pain.
Local anesthesia started with discovery of Cocaine in 1860.
Followed by developments of Novocaine 1904 and lignocaine in 1942 by Lofgren.
It became the gold standard drug compared to other local anesthetic.
Later, several new drugs were discovered such as:Bupivacaine, Articaine, Mepivicaine etc. Articaine Hydrochloride (HCL) was available in Germany since 1976.
It's the only amide local anesthesia containing ester group in its molecular structure leading to metabolizing of the drug by both plasma esterases and liver microsomal enzymes, the clinical efficacy and advantages of articaine is the duration of its anesthetic effect and its superior diffusion through the bony tissue.
Study Type
Interventional
Enrollment (Anticipated)
46
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
8 years to 10 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Children aged 8-10 years old
- Mentally capable of communication
- Cooperative children need restorative treatment
Exclusion Criteria:
- Medically compromised patient
- Primary teeth requiring pulpotomy or pulpectomy
- Parent or guardians who refuse participating in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Artinibsa
Powerful local anesthetic with short time for patients who can not tolerate normal doses of vasoconstrictor latency. High lipid solubility gives a better diffusion through the soft tissue and bone being very effective in infiltrative techniques. Duration: Latency time: 2 minutes Each mL contains: 4%Articaine 1:100000. Hydrochloride 40.00 mg, Epinephrine (D.C.I) 0.005 mg tartrate |
local anaesthetic solution with a short latency time.
Its high lipid solubility gives it better diffusion through soft tissues and bone and makes it highly effective for infiltrative techniques.Each ml contains 4%Articaine 1:100000.
|
|
Experimental: Artpharma
Its a special amide local anesthetic contain 4% articaine with epinephrine 1/200000 as a vasoconstrictor ,Contains only sulfite as a stabilizer (max 0.31 mg)
|
Its a special amide local anesthetic contain 4% articaine with epinephrine 1/200000 as a vasoconstrictor ,Contains only sulfite as a stabilizer (max 0.31 mg)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intraoperative Pain: Wong Baker rating scale
Time Frame: During the procedure.
|
Measuring by using Wong Baker rating scale the measuring unite is :Scale (0-10) including six faces.
|
During the procedure.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Onset of anesthesia
Time Frame: Immediately after the injection.
|
is measuring by using stop watch and the unite is minutes.
the unit is : minutes
|
Immediately after the injection.
|
|
The sensation after injection
Time Frame: Immediately after the injection.
|
Evaluating the effect of the anesthesia by checking mucosa using the probe and measuring unite is binary (Yes or No)
|
Immediately after the injection.
|
|
Time of numbness disappear
Time Frame: 2 hours postoperatively after the procedure.
|
Time of disappearance of numbness sensation by asking the parent/child and measuring is binary (Yes or No).
|
2 hours postoperatively after the procedure.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
April 1, 2020
Primary Completion (Anticipated)
April 1, 2021
Study Completion (Anticipated)
October 1, 2021
Study Registration Dates
First Submitted
March 3, 2020
First Submitted That Met QC Criteria
March 10, 2020
First Posted (Actual)
March 11, 2020
Study Record Updates
Last Update Posted (Actual)
March 11, 2020
Last Update Submitted That Met QC Criteria
March 10, 2020
Last Verified
March 1, 2020
More Information
Terms related to this study
Other Study ID Numbers
- CEBD-CU-2020-03-08
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.